DENVER, Jan. 19, 2023 /CNW/ – Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO: MYCO) (OTC: MYCOF) (FSE: ONFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that, in connection with its previously announced Common Share…


Previous articleNuminus Wellness Inc. Reports Q1 2023 Results
Next articleBexson Biomedical Issued USPTO Patent on Proprietary Formulation Technology, SEVALENT™